{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:14:39Z","timestamp":1790738079821,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,5]]},"abstract":"<jats:p>Malaria chemoprophylaxis has become increasingly prominent now that it is used for vulnerable populations in endemic regions in addition to nonimmune travelers to those regions. The objective would be a drug with &gt; 95% efficacy and that is easily tolerated, including in children and pregnant women. For individuals who prefer weekly rather than daily drug administration, a further objective is a product that is administered weekly. The deficiencies of present agents are parasite resistance to chloroquine, neuropsychiatric liability of mefloquine, the need for daily dosing for atovaquone\u2013proguanil, and daily dosing plus adverse reactions for doxycycline. A primaquine analogue, tafenoquine, has a 17-day half-life and was approved for weekly prophylaxis in the United States and in Australia in 2018. Weekly tafenoquine was equal to mefloquine in efficacy in nonimmunes. The tafenoquine label contains a contraindication for preexisting psychosis, but not for the broad number of other neuropsychiatric disorders which are listed as contraindications in the mefloquine label. As an 8-aminoquinoline, tafenoquine is contraindicated for glucose-6-phosphate dehydrogenase (G6PD)-deficient persons or in pregnancy if the fetus might be G6PD deficient. Other possible significant adverse reactions for tafenoquine are declines in hemoglobin levels reported in some G6PD-normal patients, asymptomatic elevations in methemoglobin, and minor psychiatric events. The lack of broad neuropsychiatric adverse reactions suggests that tafenoquine may have a role as the weekly prophylactic of choice for G6PD-normal persons.<\/jats:p>","DOI":"10.4269\/ajtmh.19-0001","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T07:02:18Z","timestamp":1552978938000},"page":"1301-1304","source":"Crossref","is-referenced-by-count":8,"title":["Approval of Tafenoquine for Malaria Chemoprophylaxis"],"prefix":"10.4269","volume":"100","author":[{"given":"Jonathan D.","family":"Berman","sequence":"first","affiliation":[{"name":"Fast Track Drugs and Biologics, North Potomac, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"PLoS Med","first-page":"e3","article-title":"Intermittent presumptive treatment for malaria","volume":"2","author":"White","year":"2005"},{"key":"b2","series-title":"For the Record: A History of Malaria Chemoprophylaxis","author":"Magill","year":"2016"},{"key":"b3","series-title":"Br Med J","first-page":"568","article-title":"Chemotherapy and chemoprophylaxis of malaria; clinical trials in 500 cases and mass prophylaxis in a hyperendemic area","volume":"1","author":"Chaudhuri","year":"1952"},{"key":"b4","series-title":"Clin Infect Dis","first-page":"320","article-title":"History of malaria in the United States Naval Forces at war: World War I through the Vietnam conflict","volume":"16","author":"Beadle","year":"1993"},{"key":"b5","series-title":"Doxteric Label","author":"Mayne","year":"1967"},{"key":"b6","series-title":"Lancet","first-page":"848","article-title":"Long-term malaria prophylaxis with weekly mefloquine","volume":"341","author":"Lobel","year":"1993"},{"key":"b7","series-title":"Mefloquine Label","author":"Roxane Laboratories","year":"2013"},{"key":"b8","series-title":"Malarone Label","author":"Glaxo"},{"key":"b9","series-title":"Am J Trop Med Hyg","first-page":"1131","article-title":"Chemosuppressive field trials in Thailand. IV. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by mefloquine (WR 142,490, A 4-quinolinemethanol)","volume":"29","author":"Pearlman","year":"1980"},{"key":"b10","series-title":"Nat Med","first-page":"917","article-title":"Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic","volume":"23","author":"Blasco","year":"2017"},{"key":"b11","series-title":"Malar J","first-page":"240","article-title":"Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil","volume":"7","author":"Sutherland","year":"2008"},{"key":"b12","series-title":"Malar J","first-page":"187","article-title":"Designing the next generation of medicines for malaria control and eradication","volume":"12","author":"Burrows","year":"2013"},{"key":"b13","series-title":"Am J Trop Med Hyg","first-page":"317","article-title":"Adult malaria chemoprophylaxis prescribing patterns in the military health system from 2007\u20132011","volume":"89","author":"Kersgard","year":"2013"},{"key":"b14","series-title":"Review of Central Nervous System Adverse Events Related to the Antimalarial Drug, Mefloquine (1985\u20131990)","author":"WHO","year":"1992"},{"key":"b15","series-title":"Am J Trop Med Hyg","first-page":"584","article-title":"Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American soldiers in Afghanistan","volume":"93","author":"Saunders","year":"2015"},{"key":"b16","series-title":"Malaria in CDC Yellow Book 2018","author":"Arguin","year":"2018"},{"key":"b17","series-title":"Am J Trop Med Hyg","first-page":"402","article-title":"Primaquine: report from CDC expert meeting on malaria chemoprophylaxis","volume":"75","author":"Hill","year":"2006"},{"key":"b18","series-title":"ARAKOTA Label","author":"60 Degrees Pharmaceuticals","year":"2018"},{"key":"b19","series-title":"Antimicrob Agents Chemother","first-page":"792","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","volume":"54","author":"Nasveld","year":"2010"},{"key":"b20","series-title":"Malar J","first-page":"49","article-title":"A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area","volume":"13","author":"Dow","year":"2014"},{"key":"b21","series-title":"Malar J","first-page":"141","article-title":"Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections","volume":"13","author":"Li","year":"2014"},{"key":"b22","series-title":"Clin Infect Dis","article-title":"Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blinded, placebo-controlled phase 1b study","author":"McCarthy","year":"2018"},{"key":"b23","series-title":"Krintofel label","author":"GlaxoSmithKline","year":"2018"},{"key":"b24","series-title":"N Engl J Med","first-page":"215","article-title":"Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria","volume":"380","author":"Lacerda","year":"2019"},{"key":"b25","series-title":"N Eng J Med","first-page":"169","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"324","author":"Beutler","year":"1991"},{"key":"b26","series-title":"Travel Med Infect Dis","first-page":"28","article-title":"Tafenoquine is not neurotoxic following supertherapeutic dosing in rats","volume":"17","author":"Dow","year":"2017"},{"key":"b27","series-title":"Antimicrob Agents Chemother","first-page":"1045","article-title":"Mefloquine induces dose-related neurological effects in a rat model","volume":"50","author":"Dow","year":"2006"},{"key":"b28","series-title":"ARAKODA NDA Approval Letter","author":"Food and Drug Administration","year":"2018"},{"key":"b29","series-title":"Primaquine Label","author":"Sanofi-Aventis US"},{"key":"b30","series-title":"Arakoda Tablets for the Prevention of Malaria in Adults","author":"60 Degrees Pharmaceuticals","year":"2018"},{"key":"b31","series-title":"J R Soc Med","first-page":"63","article-title":"Antimalarial drugs currently in development","volume":"82","author":"Gutteridge","year":"1991"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/100\/6\/article-p1301.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/100\/6\/article-p1301.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/100\/6\/article-p1301.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T21:06:42Z","timestamp":1722460002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/100\/6\/article-p1301.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":31,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.19-0001","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]}}}